In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Geodon (Pfizer)
- INDICATIONS: Schizophrenia, bipolar I disorder
- CLASS: Antipsychotic, Antipsychotic, atypical
- HALF-LIFE: 7 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acetylcholinesterase inhibitors, Alcohol, Alfuzosin, Amitriptyline, Amoxapine, Amphetamines, Antifungals, Arsenic, Artemether/Lumefantrine, Asenapine, Astemizole, Carbamazepine, Chloroquine, Ciprofloxacin, Citalopram, CNS depressants, Conivaptan, Dasatinib, Degarelix, Dolasetron, Dopamine agonists, Dopamine agonists, Dronedarone, Food, Gadobutrol, Ketoconazole, Lapatinib, Levodopa, Levofloxacin, Lithium, Methylphenidate, Metoclopramide, Moxifloxacin, Nilotinib, Pazopanib, Pimavanserin, Pimozide, QT prolonging agents, Quinagolide, Quinine, Ranolazine, St John's Wort, Telavancin, Telithromycin, Tetrabenazine, Thioridazine, Voriconazole, Vorinostat
- See adverse reactions attributed to class:
Ziprasidone should be avoided in patients with congenital long QT syndrome or a history of cardiac arrhythmias.
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ziprasidone in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/22/2024
